# Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

> **NCT00948935** · PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 35 (actual)

## Conditions studied

- Biliary Cancer
- Cholangiocarcinoma

## Interventions

- **DRUG:** Gemcitabine, Irinotecan, Panitumumab

## Key facts

- **NCT ID:** NCT00948935
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2014-09
- **Final completion:** 2014-09-26
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2020-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00948935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00948935, "Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00948935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*